Our Strategy is Paying Off
Four marketed products with accelerating revenue; fifth pending approval in largest initial market to date
Exciting opportunities for expanded use / new indications in major markets
Maturing commercial capabilities, relationships with specialists
Diverse portfolio of 16 products, all targeting major markets
Four major products in Ph II/III, three in Ph I, four more on human development track, five in pre-clinical
Cash-flow positive business with major milestones and royalties by 2003
LSPP: Ligand Specialty Pharmaceutical Products
LCPP: Ligand Corporate Partner Products